TIGIT and neoplasm: Pre-clinical tumor studies showed that the specific co-inhibition of the TIGIT and PD-1 checkpoint axis causes a significant enhancement of anti-melanoma immune responses by increasing the effector function of cytotoxic T cells [72, 73].